Navigation Links
Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease

FORT LEE, N.J.--(BUSINESS WIRE)--Jun 21, 2007 - Neurologix, Inc. (OTCBB:NRGX) today announced the publication in the June 23 issue of the journal The Lancet of positive results from the first ever gene therapy trial for Parkinson's disease and the first report of direct gene transfer into a patient's own brain cells for any adult neurodegenerative disease.

The open label Phase 1 study, conducted in 12 patients with advanced Parkinson's disease demonstrated both a lack of adverse events related to the gene therapy procedure and statistically significant improvements from baseline in both clinical symptoms and abnormal brain metabolism (as measured by positron emission tomography, or PET scanning). Although all patients had symptoms on both sides of the body, the procedure was performed on only one side of the brain, enabling the untreated side to serve as a study control. The reported improvements were observed primarily on the treated side of the body beginning three months after the gene therapy procedure and persisted through the 12 months formal study period.

Neurologix sponsored the study as part of its ongoing efforts to develop this and other gene therapy approaches to the treatment of neurodegenerative and metabolic diseases. Principal investigators Michael G. Kaplitt, MD, PhD, and Matthew J. During, MD, PhD, performed the procedures at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. Andrew Feigin, MD and David Eidelberg, MD of the Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System performed the clinical evaluations and the PET scans. Neurologix scientists were also co-investigators in the study.

"This ground-breaking study represents not only an encouraging first step in the development of a promising new approach to Parkinson's disease therapy, but also provides a platform to translate a variety of new gene therapy agents into human clinical
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
(Date:1/14/2014)... /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - a ... to place and insert the screw accurately - offers ... ligament) repair or reconstruction as it holds the bones ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw ...
(Date:1/14/2014)... Jan. 14, 2014   Oligomerix, Inc. , a privately held ... Alzheimer,s disease (AD) and related neurodegenerative disorders, announced today ... Valhalla, NY as of January 15, 2014 ... New York Medical College. Oligomerix, which is ...
Breaking Medicine Technology:Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... March 16 Sigma-Aldrich® (Nasdaq: SIAL ) ... Ace Animals, Inc., a Berks County, PA. -based ... industry. Ace Animals ( www.aceanimals.com ), a commercial rodent ... contract breeding services, and will operate as part of ...
... , INDIANAPOLIS and MELBOURNE, Australia , ... (NYSE: LLY ) and Acrux (ASX: ACR) ... worldwide license agreement for the potential commercialization of Acrux,s ... drug application for AXIRON is currently under regulatory review ...
Cached Medicine Technology:Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 2Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 3Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 4Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 5Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 6Sigma-Aldrich Further Expands In Vivo Biology Offering by Signing an Agreement to Acquire Ace Animals, Inc. 7Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 2Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 3Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 4Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux 5
(Date:7/9/2014)... Cup highlights, Brian Williams refreshing old school rap classics, ... railings. A University of Colorado Cancer Center study published ... YouTube also allows researchers, journals, and health advocates to ... cancer and prevention. , "No matter what field you,re ... communicate around the world," says Chante Karimkhani, MD candidate ...
(Date:7/9/2014)... Infectious Diseases (NIAID), part of the National Institutes ... of CRS3123, an investigational oral antibiotic intended to ... ) infection. CRS3123 (previously known as REP3123) is ... while sparing normal intestinal bacteria. , The Phase ... men and women ages 18 to 45 in ...
(Date:7/9/2014)... (July 9, 2014) A retrospective study conducted by ... colleagues reports that among adults with intellectual and developmental ... number of years receiving dental care increased. The findings, ... in Dentistry , may help improve interventions designed to ... , The researchers reviewed the dental records of ...
(Date:7/9/2014)... age with kidney and heart disease have raised concerns ... adults. However, in the first study to look closely ... Medicine at the University of Pennsylvania report that older ... expectancy and cardiovascular health as very healthy older people ... the ever increasing organ transplant waitlists, the authors of ...
(Date:7/9/2014)... published in the scientific journal Nature Neuroscience ... at Universit Laval, reveals that it is possible to ... rekindling pain so that it can subsequently be erased. ... chronic pain. , The researchers from the Faculty of ... mentale de Qubec (IUSMQ) were inspired by previous work ...
Breaking Medicine News(10 mins):Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2Health News:Discovery of a new means to erase pain 2
... experts issues a bold call to the Global Fund to ... salaries of health workers or else risk a situation in ... poor countries but there are no health professionals to deliver ... Global Fund," say Gorik Ooms (Medecins Sans Fronti?¨res, Belgium) and ...
... 'out-of-control' behavior that led to her stint in a rehab.// ... is blaming her parents for 'where she is at today ... of control' when her bizarre behavior landed her in the ... Page Six Friday, Jamie sided with Britney's manager Larry Rudolph, ...
... a Mediterranean country, is considered notoriously image-conscious. It may be ... clashing fiercely all the time. ,But the thirst ... ,Only that should explain why the Fist National Bank has ... ,Its website dubs the 'plastic surgery loans' as ...
... heart and headaches at Thomas Jefferson University Hospital are combining ... the cause// of some forms of migraine headaches. ... Center are enrolling participants in a blinded study to determine ... or flap that can allow blood to flow between the ...
... is the turn of beef products to be recalled on ... coli outbreak. Four of the five reporting// symptoms of the ... or Escherichia coli, is a common and ordinarily harmless bacteria, ... kidney failure, blindness, paralysis and sometimes death. ,E. ...
... monthly bleeding in women or menstruation may come as welcome relief ... it to be the symbol of fertility and would not like ... ,This has created a major uproar in the health world resulting ... pill called Lybrel. This pill is designed to eliminate periods as ...
Cached Medicine News:Health News:Health Expert’s Appeal to Global Fund to Fight HIV, TB and Malari 2Health News:Loans for Cosmetic Surgery in Lebanon 2Health News:Jefferson Researchers Want to Learn If Heart Defect 'at Heart' of Some Migraines 2Health News:E Coli Outbreak Forces Large-scale Recall of Beef Products 2Health News:Period Eliminating Pills 2
... Pneumoniae Antibody (IgG) Test is a semiquantitative ... clinically significant IgG antibodies to M. pneumoniae ... The test should not be used for ... Antibody (IgM) Test and is not intended ...
... is a qualitative enzyme immunoassay (EIA) ... virus capsid antigen (EBV-VCA), Epstein-Barr early ... Toxoplasma. When used in conjunction with ... in the serodiagnosis of infectious (EBV) ...
... ImmunoDOT TORCH Test is an ... for determining the presence of ... virus, cytomegalovirus and herpes simplex ... whole blood to indicate previous ...
... DotBlot G Tests are qualitative enzyme immunoassays ... burgdorferi antibodies (IgG or IgM, respectively) in ... tests should be supplemented with a standardized ... be used to support a clinical diagnosis ...
Medicine Products: